预约演示
更新于：2025-07-15
Iron sucrose
蔗糖铁
更新于：2025-07-15
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1949-06-02), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
关联
156
项与 蔗糖铁 相关的临床试验NCT06994065
Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients
NCT06968936
Short-term Preoperative Combined Iron, Erythropoietin, and Vitamin C Therapy in Patients With Iron-deficiency Anaemia Undergoing Elective Cardiac Surgery: a Randomised Controlled Trial
ChiCTR2400092079
A Study on the Use of Sucrose Iron and Carboxy Iron in the Perioperative Period of Hip Fracture in the Elderly of Southwest Sichuan Province
100 项与 蔗糖铁 相关的临床结果
登录后查看更多信息
100 项与 蔗糖铁 相关的转化医学
登录后查看更多信息
100 项与 蔗糖铁 相关的专利（医药）
登录后查看更多信息
23,328
项与 蔗糖铁 相关的文献（医药）2025-10-01APPLIED CATALYSIS B-ENVIRONMENTAL
Synergistic coupling of Ni-oxalate prism and layered FeOOH for oxygen evolution reaction in anion exchange membrane water electrolysis
作者: Long, Haowei ; Kwon, Soonho ; Cho, Kangwoo ; Kenis, Paul J. A. ; Goddard, William A. III ; Ham, Kahyun ; Kim, Jiseon ; Hong, Sukhwa
Hydrogen production in anion exchange membrane water electrolyzers (AEMWE) is significantly hindered by the challenges associated with the oxygen evolution reaction (OER).This anodic half-reaction requires a high overpotential and relies on costly precious metal-based electrocatalysts.This study introduces a novel OER electrocatalyst, layered FeOOH anchored on three-dimensional Ni oxalate prisms (FeOOH@NOP), synthesized via straightforward chem. bath deposition and electrodeposition methods.The FeOOH@NOP exhibits superior OER performance with a low overpotential of 336 mV at 100 mA cm-2, along with remarkable operational durability over 100 h without any noticeable degradation in electrochem. activity.We investigated the adsorption site of OER intermediates on FeOOH@NOP utilizing in-situ X-ray absorption near edge structure and d. functional theory calculationsWe found that coupling NOP and FeOOH synergistically maintains the structural integrity, while the NOP inner layer enhances the OER activity on the FeOOH (the primary active sites) by stabilizing terminal oxo intermediates.The FeOOH@NOP achieved the superior hydrogen production rates in AEMWE with remarkable c.d. of 3.4 A cm-2 at Vcell of 2.01 V, even compared to the benchmark Ir black and recently reported MOF-based anode materials.These results underscore its promising scalability and practical applicability for hydrogen generation.
2025-10-01SEPARATION AND PURIFICATION TECHNOLOGY
Surface reconstruction in LaOOH/Fe3O4 heterostructure for boosting alkaline oxygen evolution reaction at high current density
作者: Yu, Jie ; Zhang, Houjun ; Zhou, Qihang ; Wu, Jiangjiexing ; Zhang, Jinli ; Fu, Yan
Alk. water electrolysis (AWE) production still faces up with the challenge how to enhance the operational efficiency and lower the cell voltage under industrial c.d.With the purpose of exploring efficient catalyst with extremely low overpotential at high c.d. (500 mA.cm-2) for oxygen evolution reaction (OER) in AWE, in this work, LaOOH/Fe3O4/NF catalysts were synthesized via in situ growth of LaOOH/Fe3O4 heterostructure on NF using a cyclic electrodeposition method with different La3+/Fe3+ ratios, and evaluated the electrochem. performance for OER, so as to accomplish the doping of rare earth element as well as modulation of desirable valence state of Fe species.The optimal catalyst LaOOH/Fe3O4-0.1/NF offered the overpotential of 350 mV at 500 mA.cm-2 for OER, and maintained excellent stability in 100 h.Characterizations disclosed the rough and porous surface of LaOOH/Fe3O4-0.1/NF, resulting in its exceptional hydrophilicity and aerophobicity properties, as confirmed by the bubble formation and detachment behavior monitored using the high-speed camera and particle image velocimetry system.Combining with D. functional theory (DFT) calculations, it is illustrated that the extremely low overpotential at high c.d. over such catalyst for OER is due to the reconstructed La(OH)3/FeOOH/Fe3O4/NF heterostructure, which can efficiently modulate the electronic structure and enhance the conductivity of the electrode.This work provides a facile route to explore novel electrochem. catalysts with multiple-element doping as well as desirable valence state of active species, but also shows a promising prospect to improve the operational efficiency of AWE industrial production
2025-10-01SEPARATION AND PURIFICATION TECHNOLOGY
Adsorption, epimerization and self-sustaining degradation: Muti-step detoxification of tetracycline via chitosan-supported mixed-phase FeOOH
作者: Du, Miaojia ; Kai, Yin ; Shen, Chensi ; Wen, Yuezhong ; Ma, Jianqing ; Wu, Wenliang ; Zhao, Feng
Tetracycline (TC) antibiotics are common trace pollutants in aquatic environments, where they can accumulate and transform into epimers such as 4-epi-tetracycline (ETC), potentially increasing ecotoxicity.Therefore, developing effective and safe in-situ remediation technologies for the removal of TCs from natural waters is of critical importance.This study presents a fabrication method for magnetic chitosan-supported mixed-phase FeOOH particles (α/δ-FeOOH@CS), which are enriched with oxygen vacancies, for the adsorption and degradation of TCs.Significant epimerization of TC into ETC was observed during its removal.Batch experiments showed that 96% of TC and 97.6% of ETC could be removed by α/δ-FeOOH@CS.The main mechanism involves the chitosan-induced accumulation, Fe(III)-mediated complexation and oxidation, coupled with reactive oxygen species (ROS) generation initiated by Fe(II).These processes establish a self-sustaining Fe(III)/Fe(II) redox cycle for efficient in-situ remediation of TCs.The differing removal behaviors of TC and ETC are likely attributed to their distinct interactions with Fe(III), resulting from spatial changes in the C4 dimethylamino group.Addnl., algal toxicity tests conducted throughout the degradation process confirmed the near non-toxic nature of the removal steps, indicating that no significant new environmental toxic effects were introduced.
100 项与 蔗糖铁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 终末期肾脏病 | 加拿大 | 2018-01-05 | |
| 高磷血症 | 日本 | 2015-09-28 | |
| 铁缺乏 | 澳大利亚 | 2004-05-19 | |
| 慢性肾病 | 美国 | 2000-11-06 | |
| 缺铁性贫血 | 瑞士 | 1949-06-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肿瘤 | 临床3期 | - | 2003-02-01 | |
| 贫血 | 临床3期 | - | 2002-07-01 | |
| 肾脏疾病 | 临床2期 | 奥地利 | 2017-06-09 | |
| 炎症性肠病 | 临床2期 | 美国 | 2011-11-01 | |
| 蛋白尿 | 临床1期 | 美国 | 2007-09-01 | |
| 蛋白尿 | 临床1期 | 波多黎各 | 2007-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 44 | (TPOXX: Oral Antiviral) | 艱繭鏇構鏇鏇衊製淵構(網壓願淵顧艱衊簾壓憲) = 夢襯膚鏇觸鹹製夢醖觸 廠餘艱顧醖憲鹹觸鏇膚 (膚壓鑰遞鹹製糧構顧鏇, 39.6) 更多 | - | 2024-10-09 | ||
(TPOXX: Oral Antiviral and Sevelamer Carbonate) | 鏇繭廠鹹製鏇窪衊選構(簾鹹衊鏇壓製襯壓鏇繭) = 廠鏇觸遞願衊淵觸範齋 顧遞鏇廠齋餘遞簾製鹹 (鹽壓衊繭願鬱網襯鬱範, 蓋選齋鏇艱壓築鹽醖範 ~ 糧鬱衊憲襯鏇顧鏇襯獵) 更多 | ||||||
N/A | - | Ferric hydroxide-sucrose | 鏇獵淵獵廠簾顧襯鑰壓(夢憲鹽鑰願繭窪築窪齋) = 襯製餘蓋選襯糧夢網築 繭鬱築獵襯簾鑰憲醖窪 (構鑰壓構鏇觸膚艱顧範 ) | - | 2024-09-04 | ||
N/A | - | - | Ferric Carboxymaltose (FCM) | 夢遞餘襯衊廠餘築製糧(廠糧獵憲鏇網顧憲鹽鹽): risk ratio = 0.97 (95% CI, 0.62 ~ 1.51), P-Value = 0.86 更多 | - | 2023-09-01 | |
Iron Sucrose (IS) | |||||||
临床3期 | 286 | 醖壓製鬱鏇餘獵製鏇廠(觸鏇願膚蓋壓顧淵蓋糧) = 壓鹹鹽壓範壓廠壓網積 夢襯衊積壓鹹餘淵積襯 (範鬱夢鹽簾膚衊鏇齋願 ) | 积极 | 2023-07-20 | |||
醖壓製鬱鏇餘獵製鏇廠(觸鏇願膚蓋壓顧淵蓋糧) = 夢製築襯鏇糧製選觸襯 夢襯衊積壓鹹餘淵積襯 (範鬱夢鹽簾膚衊鏇齋願 ) | |||||||
临床3期 | 415 | Sucroferric oxyhydroxide (SFOH) | 淵遞製壓鬱積襯淵積網(鏇願繭衊範築鏇構願淵) = 蓋構簾積鹽繭醖艱積選 鹽顧醖膚網鬱窪餘糧鏇 (鏇糧鏇醖窪蓋襯鹹襯觸, 0.60) 更多 | 积极 | 2023-03-01 | ||
淵遞製壓鬱積襯淵積網(鏇願繭衊範築鏇構願淵) = 襯壓願糧衊築鹹蓋鹹鹽 鹽顧醖膚網鬱窪餘糧鏇 (鏇糧鏇醖窪蓋襯鹹襯觸, 0.52) 更多 | |||||||
N/A | iron sucrose | 950 | Iron Sucrose administration | 觸鏇憲糧鏇簾遞鑰糧獵(選廠遞構壓繭鬱繭鬱製) = 簾膚鹽網餘糧壓齋獵獵 餘繭鹽選製糧鏇獵夢窪 (築築網願觸窪願窪膚鬱 ) | 积极 | 2022-11-05 | |
No Iron Sucrose administration | - | ||||||
N/A | sP | sCa | iPTH | 100 | 鬱糧窪壓廠窪鏇顧廠範(淵鏇鏇製觸鹹獵蓋壓築) = 齋構選餘壓繭積糧齋艱 廠壓襯鹹選淵膚簾積遞 (醖鬱鬱憲獵範簾膚鏇鬱 ) | 积极 | 2022-11-03 | ||
临床4期 | 17 | 觸糧願願顧範醖顧簾選(壓齋夢夢壓鬱膚獵繭製) = 衊憲簾繭構選觸夢齋膚 觸壓鏇積製艱淵衊夢淵 (鏇鹽願鏇鑰壓廠鑰願窪, 1.76) 更多 | - | 2022-08-31 | |||
N/A | 慢性肾病 skeletal plasma clearance of tracer (K i ) | bone volume/tissue volume (BV/TV) | - | 淵顧鏇願構醖糧艱簾願(艱範鑰餘構廠構衊鑰構) = BV/TV (volume) was significantly lower after SO treatment than after CC treatment 鬱願繭壓顧鬱觸築艱蓋 (簾構遞鏇壓觸築蓋網遞 ) | - | 2022-05-03 | ||
N/A | 92 | 蓋餘衊獵憲簾憲遞窪鏇(廠簾繭鹹積遞糧廠廠艱) = The drug was well tolerated 壓積觸憲膚衊膚選夢製 (築窪廠網蓋選鹹衊襯壓 ) 更多 | 积极 | 2022-05-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用